datopotamab deruxtecan + rilvegostomig + carboplatin

This is an investigational **combination therapy** comprising **datopotamab deruxtecan** (Dato-DXd, a TROP2-directed antibody-drug conjugate developed by Daiichi Sankyo/AstraZeneca), **rilvegostomig** (AZD2936, a bispecific monoclonal antibody targeting PD-1 and TIGIT from AstraZeneca), and **carboplatin** (a platinum-based chemotherapeutic). The triplet is studied as first-line or adjuvant therapy in non-small cell lung cancer (NSCLC), including in operable stage I adenocarcinoma (ctDNA-positive or high-risk pathological features) and advanced/metastatic settings. Datopotamab deruxtecan delivers a topoisomerase I inhibitor payload selectively to TROP2-expressing tumor cells. Rilvegostomig provides dual immune checkpoint inhibition via PD-1 and TIGIT pathways to enhance antitumor immunity. Carboplatin causes DNA cross-linking and cytotoxicity in rapidly dividing cells. This combination is primarily under investigation for its potential antineoplastic effects in NSCLC and is not approved for general cancer therapy at this time[1][2][4][5].

Other names

datopotamab deruxtecan + rilvegostomig + carboplatinDato-DXd + rilvegostomig + carboplatin